PD-1-cis-targeted IL-2Rβγ agonists showed better anti-tumor efficacy than pembrolizumab in treating the tumor model of human PD-1-transgenic mice (Figure 4F) (Table 5) (21). Here, PDCD1 is linked to neoplasm.